0.14%
0.85%
-1.12%
-0.28%
16.45%
2.61%
-28.05%
AI Spotlight on FAE
Company Description
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally.The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products.It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu.
The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems.It also exports its products.Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.
Market Data
| Last Price | 3.54 |
| Change Percentage | 0.14% |
| Open | 3.52 |
| Previous Close | 3.54 |
| Market Cap ( Millions) | 1102 |
| Volume | 4149606 |
| Year High | 3.83 |
| Year Low | 2.91 |
| M A 50 | 3.47 |
| M A 200 | 3.57 |
Financial Ratios
| FCF Yield | 4.04% |
| Dividend Yield | 3.81% |
| ROE | 17.83% |
| Debt / Equity | 6.33% |
| Net Debt / EBIDTA | -10.68% |
| Price To Book | 1.61 |
| Price Earnings Ratio | 9.3 |
| Price To FCF | 24.78 |
| Price To sales | 1.84 |
| EV / EBITDA | 6.67 |
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceutical Specialties and Healthcare
Expected Growth : 1.2 %
What the company do ?
Pharmaceutical Specialties and Healthcare from Faes Farma, S.A. develops and commercializes pharmaceutical products, focusing on prescription and over-the-counter medications.
Why we expect these perspectives ?
Faes Farma's 1.2% growth in Pharmaceutical Specialties and Healthcare is driven by increasing demand for chronic disease treatments, an aging population, and strategic partnerships. Additionally, the company's focus on R&D, expansion into emerging markets, and cost-saving initiatives contribute to its growth momentum.
Segment n°2 -> Nutrition and Animal Health
Expected Growth : 0.8 %
What the company do ?
Nutrition and Animal Health from Faes Farma, S.A. develops and manufactures nutritional supplements and health products for animals, improving their well-being and performance.
Why we expect these perspectives ?
Faes Farma's Nutrition and Animal Health segment growth of 0.8 is driven by increasing demand for animal feed additives, expansion into emerging markets, and strategic partnerships. Additionally, growing consumer awareness of animal welfare and sustainable farming practices contribute to the segment's growth.
Segment n°3 -> Others
Expected Growth : 0.5 %
What the company do ?
Others from Faes Farma, S.A. refers to the miscellaneous products and services offered by the company, excluding its pharmaceutical and healthcare segments.
Why we expect these perspectives ?
Faes Farma's 0.5 growth is driven by increasing demand for its pharmaceutical products, particularly in the allergy treatment segment. Strong brand recognition, strategic partnerships, and efficient supply chain management also contribute to its growth. Additionally, the company's focus on R&D and innovation enables it to stay competitive in the market.
Faes Farma, S.A. Products
| Product Range | What is it ? |
|---|---|
| Fluoxetine | An antidepressant medication used to treat depression, obsessive-compulsive disorder, and some eating disorders. |
| Omeprazole | A medication used to treat gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome. |
| Ranitidine | A medication used to treat gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other conditions caused by excess stomach acid. |
| Ciprofloxacin | An antibiotic used to treat bacterial infections, including urinary tract infections, pneumonia, and anthrax. |
| Doxycycline | An antibiotic used to treat bacterial infections, including pneumonia, acne, and Lyme disease. |
| Ibuprofen | A nonsteroidal anti-inflammatory drug (NSAID) used to treat pain, reduce inflammation, and lower fever. |
Faes Farma, S.A.'s Porter Forces
Threat Of Substitutes
Faes Farma, S.A. faces moderate threat from substitutes due to the presence of alternative pharmaceutical products in the market.
Bargaining Power Of Customers
Faes Farma, S.A. has a diverse customer base, which reduces the bargaining power of individual customers.
Bargaining Power Of Suppliers
Faes Farma, S.A. relies on a few key suppliers for raw materials, which gives them some bargaining power.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, but new entrants can still pose a threat to Faes Farma, S.A. due to advancements in technology and changing regulatory environments.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, and Faes Farma, S.A. faces intense rivalry from established players and new entrants.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 3.48% |
| Debt Cost | 3.95% |
| Equity Weight | 96.52% |
| Equity Cost | 6.31% |
| WACC | 6.23% |
| Leverage | 3.61% |
Faes Farma, S.A. : Quality Control
Faes Farma, S.A. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| VETO.PA | Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas … |
| SECARE.ST | Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the … |
| FAGR.BR | Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it … |
| RJF.MC | Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include … |
| BOI.PA | Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Faes Farma
A-Score
1-Year Total Return ->
🥈
Reig Jofre
A-Score
1-Year Total Return ->
🥉
Fagron
A-Score
1-Year Total Return ->
4
Boiron
A-Score
1-Year Total Return ->
5
Vetoquinol
A-Score
1-Year Total Return ->
6
